Viewing nowRibonelle 150 mg (Risedronate Sodium 2.5 Hydrate)
Risedronate Sodium 2.5 Hydrate 172.1mg
Tablet · Prescription medication
Gunil Biopharm Co., Ltd.

MFDS item code 201905603 · Approved 2019.08.08 · Insurance code 073001340
Treatment and prevention of osteoporosis in postmenopausal women
Osteoporosis occurring in postmenopausal women is a disease characterized by reduced bone density, leading to an increased risk of fractures. This medication helps maintain bone density in postmenopausal women and prevents their bones from becoming weak. It is also effective in treating already existing osteoporosis. It plays an important role in reducing fracture risk and maintaining healthy bones. Therefore, it is used for the treatment and prevention of osteoporosis in postmenopausal women.
1. Adults : Administer 150 mg of risedronate sodium orally once monthly. 2. Elderly patients : Since the bioavailability and pharmacodynamics of this medicine in elderly patients (over 60 years) are similar to those in younger people, no dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with creatinine clearance of 30 mL/min or higher. This medicine is contraindicated in patients with severe renal impairment and creatinine clearance below 30 mL/min. ○ Food interferes with the absorption of this medicine; for adequate absorption, take it at least 30 minutes before consuming food or any beverage other than water for the first time that day. To help this medicine reach the stomach easily and reduce the possibility of esophageal irritation, take it in an upright position with a sufficient amount of plain water (170 ∼ 230 mL). Taking this medicine with other beverages, including mineral water, may reduce its absorption. Do not chew or suck this medicine because of the possibility of oropharyngeal ulceration. Patients should not lie down for at least 30 minutes after taking it. ○ If a patient forgets to take this medicine on the scheduled day, take it as follows. - If the next scheduled dose is 7 days or more away, take 1 tablet the next morning after remembering. Take the next dose on the originally scheduled day. Do not take more than 1 tablet of this medicine within 7 days. - If the next scheduled dose is within 7 days, wait until the originally scheduled dose day and then take 1 tablet.
3. Children : The safety and efficacy in children under 18 years of age have not been established.
This medication may irritate the gastric mucosa, so patients with esophageal or gastric diseases should exercise caution. Symptoms such as dysphagia, retrosternal pain, and heartburn may occur, and if these symptoms develop, the medication should be discontinued immediately and a physician consulted. It should be taken with a sufficient amount of water and the patient should not lie down for at least 30 minutes after taking it. This medication should not be used by patients with certain esophageal conditions, hypocalcemia, or severely impaired kidney function, as well as by pregnant and nursing women. Additionally, it should not be administered to patients with lactose intolerance. This medication contains the dye Yellow No. 5, and caution should be exercised if there is an allergy to this ingredient. Rarely, severe side effects such as osteonecrosis of the jaw and atypical femoral fractures may occur with long-term use, therefore regular check-ups are necessary. The absorption can be impaired if taken with supplements or antacids containing calcium, magnesium, iron, etc., so an interval should be observed. Pregnant women or women who may become pregnant should avoid taking it, and nursing mothers should also discontinue taking or nursing. The safety and efficacy in children have not been established, and elderly patients do not require special caution. In the event of an overdose, calcium levels may drop, necessitating immediate medical assistance, and gastric lavage or calcium supplementation may be required. This medication should be kept out of reach of children and should not be transferred to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in an airtight, closed container at room temperature between 1 and 30 degrees Celsius. This will help maintain the drug's effectiveness and prevent deterioration.
Bright blue oval film-coated tablet
1 tablet/PTP
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRisedronate Sodium 2.5 Hydrate 172.1mg
Tablet · Prescription medication
Gunil Biopharm Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Austin Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Nexpam Korea Co., Ltd.

Risedronate Sodium 2.5 Hydrate 35mg
Tablet · Prescription medication
Hyutecs Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.2mg
Tablet · Prescription medication
Celix Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Myeongmun Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Korea United Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.